2013 POSTGRADUATE COURSE SYLLABUS

Program Description, Faculty Listing and Disclosure Information ........................................... 7
Course Evaluation and CME Information ................................................................................... 11

SATURDAY MORNING, OCTOBER 13, 2013

Session 1A: Luminal GI Conditions
Moderator: Lawrence J. Brandt, MD, MACG

New Insights on Gluten Intolerance ................................................................. 15
Sheila E. Crowe, MD, FACG
Elucidate the diagnostic and treatment strategies in celiac disease and gluten intolerance.

Diverticular Disease as a Chronic Illness: Evolving Epidemiologic and Clinical Insights .......... 19
Brennan M. R. Spiegel, MD, MSHS, FACG
Address the epidemiology, pathophysiology, and management of chronic, symptomatic diverticular disease.

Clostridium difficile: New Weapons Against an Old Enemy .................................................. 27
Neil H. Stollman, MD, FACG
Discuss new approaches in treating Clostridium difficile colitis and improving outcomes.

Ischemic Colitis: What Is New? ................................................................. 31
Lawrence J. Brandt, MD, MACG
Review advances in the diagnosis, pathophysiology and treatment of ischemic colitis.

The David Sun Lecture: Gastroenterology and Public Health in the Era of Health Reform
Howard K. Koh, MD, MPH

Session 1B: Gastrointestinal Bleeding: Maximizing Outcomes and Minimizing Risks
Moderator: Loren A. Laine, MD, FACG

Obscure Small Bowel Bleeding: Capsules, Balloons, Catheters, and Scanners ................. 35
John A. Martin, MD
Describe the various modalities in detecting the cause and location of obscure small bowel bleeding.

Non-variceal Upper GI Bleeding .............................................................................. 38
Alan N. Barkun, MD, CM, MSc (Clinical Epi.), FACG
Provide updates on the role of endoscopy and management approaches for non-variceal upper GI bleeding.

Variceal GI Bleeding .............................................................................................. 44
Loren A. Laine, MD, FACG
Review new techniques and treatment strategies in controlling variceal GI bleeds.

Lower GI Bleeding ................................................................................................. 46
Dennis M. Jensen, MD, FACG
Review the causes, diagnostic approaches and management of lower GI bleeding.

Please note: While evaluations for CME credit can ONLY be completed online (at www.amevaluations2013.gi.org), information corresponding to the online evaluation is provided on page 11 to assist you.
Saturday Learning Luncheons

1. Treatment of Refractory GERD and Functional Chest Pain .......................................................... 51
   Ronnie Fass, MD, FACP
   Recommend the evaluation and treatment of GERD patients who are unresponsive or partially respond to PPIs and patients with functional chest pain.

2. Esophageal and Anorectal Manometry: When to Order, How Does It Help in Patient Management? ........ 55
   Jeffrey L. Conklin, MD, FACP
   Characterize the utility of esophageal and anorectal manometry in the evaluation of common GI symptoms.

3. Current Management of Fecal Incontinence ................................................................. 61
   Satish S. C. Rao, MD, PhD, FACP
   Review the current management of fecal incontinence including newer treatment interventions.

4. Optimizing Colonoscopy Skills, Polyp Detection and Bowel Preparation ...................................... 65
   Douglas K. Rex, MD, MACG
   Discuss techniques to improve colonoscopy outcomes.

5. The Use of Electrosurgical Equipment for the Practicing Gastroenterologist .................................. 69
   Priya Jamidar, MD, FACP
   Provide understanding of the electrosurgical equipment principles, safety and applications in endoscopy.

6. Management of Chronic Abdominal Pain ................................................................. 73
   Douglas A. Drossman, MD, MACG
   Discuss the multidimensional approach in managing patients with chronic abdominal pain.

7. Medico-legal Aspects of ERCP ................................................................. 81
   Peter B. Cotton, MD, FACP
   Discuss strategies to decrease the risk of litigation related the practice of ERCP.

8. What Is New in Diagnostic and Interventional EUS ................................................................. 86
   Norio Fukami, MD, FACP
   Provide updates on the diagnostic and interventional utility of endoscopic ultrasound in GI disease.

9. HCV: Treat Now or Wait for IFN-free ................................................................. 87
    David R. Nelson, MD, FACP
    Facilitate selection of the optimal time to initiate therapy for hepatitis C in an environment of rapidly evolving therapeutic choices.

10. Evaluation and Treatment of Ascites ................................................................. 89
    David G. Koch, MD, MSCR
    Discuss the diagnostic evaluation and treatment of ascites.

11. Pancreatic Cysts ................................................................. 91
    Jonathan M. Buscaglia, MD
    Discuss the diagnostic options for the evaluation of pancreatic cysts and the new International Association of Pancreatology management guidelines.

12. The Inpatient Consult for Elevated Liver Enzymes ................................................................. 93
    Norah A. Terrault, MD, MPH, FACP
    Discuss the assessment of elevated liver function tests in hospitalized patients.

Session 1C: Advances in Inflammatory Bowel Disease

Moderator: David T. Rubin, MD, FACP

Cancer Screening in IBD ................................................................. 97
David T. Rubin, MD, FACP
Provide guidance on cancer screening in patients with inflammatory bowel disease and the management of dysplasia-associated lesions or masses (DALMs) and sporadic adenomas.

Perianal Disease in Crohn’s Disease ................................................................. 102
David A. Schwartz, MD, FACP
Review the assessment and treatment of perianal disease in patients with Crohn’s disease.

Optimal Use of Immunomodulators and Biologics ................................................................. 109
Edward V. Loftus, Jr., MD, FACP
Discuss how to optimize the use of immunomodulators and biologic therapies in the treatment of inflammatory bowel disease.

New Therapeutic Agents in IBD ................................................................. 114
William J. Sandborn, MD, FACP
Discuss the novel therapeutic agents for the treatment of inflammatory bowel disease.
Simultaneous Symposia Sessions

Symposium A: Endoscopic Therapies for Barrett’s Esophagus with High Grade Dysplasia (HGD) or Early Cancer: A Multitude of Choices  
Moderator: Michael B. Wallace, MD, MPH, FACG

The Role of Ablation .............................................................................................................. 116  
Kenneth K. Wang, MD, FACG  
*Describe the available options for ablative therapy and facilitate the choice of ablative therapy in Barrett’s esophagus with HGD or early cancer.*

The Role of Endoscopic Mucosal Resection (EMR) ............................................................. 119  
Michael B. Wallace, MD, MPH, FACG  
*Describe the role of EMR for the therapy of Barrett’s esophagus with HGD or early cancer.*

The Role of Endoscopic Submucosal Dissection (ESD) ....................................................... 121  
Norio Fukami, MD, FACG  
*Describe the role of ESD for the therapy of Barrett’s esophagus with HGD or early cancer.*

Symposium B: Multidisciplinary Approach to Acute Pancreatitis  
Moderator: Timothy B. Gardner, MD, FACG

Medical Management of Acute Pancreatitis ...................................................................... 123  
Timothy B. Gardner, MD, FACG  
*Discuss medical interventions and their timing in the management of acute pancreatitis.*

Endoscopic Management of Acute Pancreatitis ................................................................ 127  
Stuart Sherman, MD, FACG  
*Discuss endoscopic interventions in the management of acute pancreatitis.*

Surgical Management of Acute Pancreatitis ..................................................................... 136  
Steven J. Hughes, MD  
*Discuss surgical options in the management of acute pancreatitis.*

Symposium C: Cholestatic Liver Disease  
Moderator: Adrian Reuben, MBBS, FACG

Drug Induced Cholestasis  
Adrian Reuben, MBBS, FACG  
*Discuss drug induced cholestasis in the differential diagnosis of cholestatic liver disease.*

PBC and PSC ....................................................................................................................... 139  
Keith D. Lindor, MD, FACG  
*Provide an update of the recent developments in the diagnosis and management of PBC and PSC.*

Cholestatic Autoimmune Hepatitis and Overlap Syndromes ........................................... 142  
Albert J. Czaja, MD, FACG  
*Discuss cholestatic autoimmune hepatitis in the differential diagnosis of cholestatic liver disease and facilitate therapeutic choices.*
**SUNDAY MORNING, OCTOBER 13, 2013**

**Session 2A: GI Endoscopy**

*Moderator:* Peter V. Draganov, MD, FACG

**Approach to Subepithelial Lesions** ............................................................ 147
Jonathan M. Buscaglia, MD
*Provide an overview of the types of subepithelial lesions, diagnostic evaluation and management algorithm.*

**Preventing Post-ERCP Pancreatitis: Have We Found the Magic Bullet?** .................. 151
Peter V. Draganov, MD, FACG
*Outline the risk factors for post-ERCP pancreatitis and provide strategies for prophylaxis.*

**Sedation for Endoscopy: What Does the Future Hold?** .................................... 160
John J. Vargo, II, MD, MPH, FACG
*Outline the choices for sedation at the time of endoscopy and discuss the current legislative landscape.*

**The New Colonoscopy Surveillance Guidelines** .................................................. 163
David A. Lieberman, MD, FACG
*Review the latest consensus guidelines on surveillance colonoscopy.*

**Session 2B: Liver Disease**

*Moderator:* David R. Nelson, MD, FACG

**Changing Treatment Paradigms for HCV** .......................................................... 165
David R. Nelson, MD, FACG
*Discuss the current choices for therapy of HCV.*

**The Risks of Surgery in Patients with Liver Disease** ......................................... 172
Joseph K. Lim, MD, FACG
*Facilitate the evaluation and risk stratification of patients with liver disease in need of possible surgery.*

**Liver Disease in Pregnancy** ................................................................................. 178
Mary E. Rinella, MD, FACG
*Discuss liver diseases in pregnancy.*

**Hepatic Encephalopathy** ....................................................................................... 182
Fred Poordad, MD
*Discuss the diagnostic evaluation and current management strategies of patients with hepatic encephalopathy.*

**Alcoholic Hepatitis** ................................................................................................ 184
David G. Koch, MD
*Discuss current management strategies of patients with alcoholic hepatitis.*

**SUNDAY AFTERNOON, OCTOBER 13, 2013**

**Sunday Learning Luncheons**

13. **Optimal Polypectomy Technique: The Search Continues** .............................. 187
Gregory G. Ginsberg, MD, FACG
*Facilitate the choice of optimal polypectomy technique.*

14. **The Changing Face of Helicobacter pylori** ..................................................... 190
William D. Chey, MD, FACG
*Summarize the current approach in detecting Helicobacter pylori before and after treatment and the recommended treatment regimens.*

15. **Management of Refractory Constipation** ...................................................... 194
Satish S. C. Rao, MD, PhD, FACG
*Review diagnostic testing and treatment in patients with chronic constipation who do not respond to traditional treatments.*

16. **Advanced Endoscopic Imaging Techniques: Making the Endoscopist Work Smarter and Not Longer** ............................. 197
Kenneth K. Wang, MD, FACG
*Discuss advanced endoscopic imaging techniques and their application in everyday practice.*

17. **The Pregnant Patient with IBD** ................................................................. 199
Sunanda V. Kane, MD, MSPH, FACG
*Describe the management approach in pregnant patients with inflammatory bowel disease.*
18. Eosinophilic Esophagitis: Guidance on Diagnosis and Treatment .......................... 201
   Nicholas J. Shaheen, MD, MPH, FACG
   Discuss updates on the diagnosis and treatment of eosinophilic esophagitis.

19. Therapy for Hepatitis C: How to Minimize and Manage Side Effects .................. 205
   Fred Poordad, MD
   Provide management strategies to minimize and manage side effects from HCV targeted therapy.

20. Non-alcoholic Fatty Liver Disease ................................................................. 207
   Mary E. Rinella, MD, FACG
   Discuss recent developments in the diagnosis and therapy of NAFLD.

21. Meaningful Interventions in Chronic Pancreatitis: When to Endoscope, When to Drain and When to Transplant
    Timothy B. Gardner, MD, FACG ................................................................. 208
    Steven J. Hughes, MD ................................................................................. 215
   Discuss current strategies for prophylaxis of post-ERCP pancreatitis and facilitate the choice of an appropriate strategy.

22. Evidence-based Medicine for the Practicing Gastroenterologist ........................... 216
   Paul Moayyedi, MB, ChB, PhD, FACG
   Provide information on how to interpret and understand the value and clinical relevance of evidence-based medicine.

23. Colorectal Cancer Screening: Medico-legal Issues ............................................. 218
   Douglas G. Adler, MD, FACG
   Explore common issues in colorectal cancer screening that lead to malpractice claims and identify strategies to minimize liability.

24. Capsule Endoscopy: Current Indications and Future Innovation ....................... 220
   Jonathan A. Leighton, MD, FACG
   Review the recommended indications for capsule endoscopy as well as future directions in its diagnostic uses.

Session 2C: Pancreaticobiliary Disease
   Moderator: Peter B. Cotton, MD, FACG

The Current State of ERCP: Where We Are and Where We Go ............................ 223
   Peter B. Cotton, MD, FACG
   Discuss quality improvement strategies and safety in the practice of ERCP.

Chronic Pancreatitis: New Insights in Etiology ................................................. 225
   Michelle A. Anderson, MD, MSc
   Discuss recent developments in our understanding of the etiology of chronic pancreatitis.

Chronic Pancreatitis: When to Scope? ............................................................... 229
   Gregory A. Coté, MD, MS
   Discuss endoscopy based therapy for chronic pancreatitis and provide guidance on when to choose endoscopic therapy.

Chronic Pancreatitis: When to Operate? ............................................................ 234
   Steven J. Hughes, MD
   Discuss surgical therapy for chronic pancreatitis and provide guidance on when to choose surgery.

Simultaneous Symposia Sessions

Symposium D: Optimizing Management of Functional Gastrointestinal Disorders
   Moderator: William D. Chey, MD, FACG

Gastroparesis: Optimizing Management and Improving Outcomes ...................... 236
   Henry P. Parkman, MD, FACG
   Discuss clinical symptoms, diagnosis and treatment approach in gastroparesis.

Bloating: Blowing Up the Old Myths on a Common Problem ............................ 240
   William D. Chey, MD, FACG
   Review the mechanisms underlying bloating and distension, and the current and emerging therapeutic approaches to effectively manage these symptoms.

Differentiating and Treating IBS-C and Chronic Constipation .......................... 243
   Lin Chang, MD, FACG
   Discuss how to diagnose and differentiate irritable bowel syndrome with constipation and chronic constipation and how this affects treatment.
Symposium E: Individualized Management in IBD
Moderator: Sunanda V. Kane, MD, MSPH, FACG

Beyond Top-down/Top-up Controversy: How to Stratify Risk in IBD and Choose Tailored Therapy ............. 246
Stephen B. Hanauer, MD, FACG
Discuss predictors of poor outcome in IBD patients and facilitate the choice of therapy based on these predictors.

Therapeutic Monitoring Optimizes Outcomes in IBD ................................................................. 248
Sunanda V. Kane, MD, MSPH, FACG
Review recommendations regarding the utility of serologic tests and drug level monitoring in patients with inflammatory bowel disease.

Dietary Intervention and Probiotics in IBD .......................................................... 251
Donald R. Duerksen, MD
Discuss dietary intervention and the use of probiotics in the treatment of inflammatory bowel disease.

Symposium F: Endoscopy in the Obese Patient
Moderator: Gregory G. Ginsberg, MD, FACG

Endoscopic Management of Bariatric Surgery Complications .................................................. 256
John A. Martin, MD
Discuss current endoscopy based options in the management of post-bariatric surgery complications.

ERCP in Patients with Altered Gastric Anatomy ............................................................... 261
Mihir S. Wagh, MD
Discuss management strategies in patients with altered gastric anatomy in need of ERCP.

Endoscopic Therapies for Obesity: Where We Are and Where We Go ........................................ 264
Gregory G. Ginsberg, MD, FACG
Discuss current and future endoscopy based therapy for obesity.